Table 1.
Patient and transplant characteristics.
| Variable | mIDH 1/2 (n=23) |
Wt IDH (n=76) |
Total (n=99) |
|---|---|---|---|
| Age at HCT | |||
| Median Range |
64.0 (36–73) |
54.0 (18–71) |
57.0 (18–73) |
|
| |||
| Sex | |||
| Male | 10(43.5%) | 36(47.4%) | 46(46.5%) |
| Female | 13(56.5%) | 40(52.6%) | 53(53.5%) |
|
| |||
| Disease status at HCT | |||
| CR-1 | 13(56.5% | 34(44.7%) | 47(47.5%) |
| 1’st Relapse | 2(8.7%) | 6(7.9%) | 8(8.1%) |
| CR-2 | 6(26.1%) | 11(14.5%) | 17(17.2%) |
| 2”nd Relapse | - | 1(1.3%) | 1(1%) |
| ≥3’rd CR | - | 3(3.9%) | 3(3%) |
| Induction Failure | 2(8.7%) | 21(27.6%) | 23(23.3%) |
|
| |||
| HLA Match Degree | |||
| HLA identical, Sibling | 7(30.4%) | 20(26.3%) | 27(27.3% |
| HLA matched, Unrelated | 4(17.4%) | 5(6.6%) | 9(9.1%) |
| HLA mismatched, Sibling | 0 | 1(1.3%) | 1(1%) |
| HLA mismatched, Unrelated | 9(39.1%) | 41(53.9%) | 50(50.5%) |
| Haploidentical | 3(13%) | 9(11.8%) | 12(12.1%) |
|
| |||
| Graft source | |||
| Bone marrow | 0(0%) | 1(1.3%) | 1(1%) |
| Cord blood | 0(0%) | 3(3.9%) | 3(3%) |
| Peripheral blood stem cells | 23(100%) | 72((94.7% | 95(96%) |
|
| |||
| CMV status | |||
| Negative | 1(4.3%) | 4(5.3%) | 5(5.1) |
| Positive | 22(95.7%) | 72((94.7%) | 94(94.9) |
|
| |||
| Regimen | |||
| RIC | 18(78.2%) | 50(65.7%) | 68(68.6%) |
| MAC | 5(21.7%) | 26(34.2%) | 31(31.3%) |
|
| |||
| GVHD prophylaxis | |||
| Tacrolimus/sirolimus | 18(78.2%) | 53(69.7%) | 71(71.7%) |
| Tacrolimus/Cytoxan | - | 10(13.1%) | 10 (10.1) |
| Tacrolimus/Cellcept | - | 4(5.2%) | 4 (4%) |
| Tacrolimus/MTX | 1(4.3%) | 5 (6.5%) | 6(6%) |
| Other | 4(17.3% | 4 (5.2%) | 8 (8%) |